Acetohydroxamic acid plus short drugs for drug-resistant TB
Part of Infections clinical trials.
This study tests a new combination of drugs for people with drug-resistant TB. It adds a medicine called acetohydroxamic acid to a short-course regimen to see if it works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed type of TB that is resistant to the usual drugs (RR-TB or MDR-TB).
- Your age must be between 14 and 64.
- You must not have HIV.
- You must not have taken certain strong TB drugs (bedaquiline, delamanid, linezolid) for more than one month before.
- You must not have severe health issues like heart failure, serious liver disease, uncontrolled diabetes, or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This trial tests a 6-month treatment for people with rifampicin-resistant tuberculosis (TB). It aims to see if a shorter, simpler regimen works as well as longer treatments. You may qualify if you have this type of TB and meet a few health requirements.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.
Hear when a new Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.